Live
On Monday, the drug major Dr Reddy’s Laboratories (DRL) said that its US subsidiary Promius Pharma has got approval from the USDFA for marketing Sernivo spray which is used in treating skin disorder.
The company said in a BSE filing that “Its US subsidiary, Promius Pharma, LLC, US has received approval for Sernivo Spray, 0.05 per cent from the US Food and Drug Administration (FDA). Sernivo Spray, a prescription topical steroid, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older.”
It further said that the commercial launch of the product is planned for the coming quarter.
